Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1 2

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Prostatic Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Hypersensitivity 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × ZD4054 × Clear all
NCT00090363 2013-01-08

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

AstraZeneca

Phase 2 Completed
447 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT00055471 2012-10-31

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

AstraZeneca

Phase 2 Completed
22 enrolled 17 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

AstraZeneca

Phase 2 Terminated
120 enrolled 8 charts

Hypersensitivity, Neoplasms

NCT00745875 2012-06-06

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

AstraZeneca

Phase 2 Completed
66 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡